GlassScriptPhysician profile
Vigyan V Bang
NPI 1790199727
$14,362.77
in general payments reported to CMS, 2019-2025
14 companies · $722 in 2025
The $722 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $987 · 2020: $1,105 · 2021: $2,747 · 2022: $2,326 · 2023: $2,468 · 2024: $4,007 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,889 · Travel and Lodging: $3,089 · Consulting Fee: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,888.72 |
| Travel and Lodging | $3,089.22 |
| Consulting Fee | $219.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $6,303.52 | 2019-2025 | Ekosonic, Avvigo Guidance System, Watchman Flx |
| Edwards Lifesciences Corporation | $2,792.09 | 2021-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Abbott Laboratories | $2,167.64 | 2021-2025 | Nc Trek Neo, Cardiomems, Xience Skypoint |
| Medtronic, INC. | $1,781.65 | 2021-2024 | Corevalve Evolut R, Endurant Iis |
| Abiomed | $517.44 | 2023-2025 | Impella |
| Jenavalve Technology, INC. | $219.49 | 2024 | |
| Astellas Pharma US INC | $174.99 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $91.61 | 2023-2025 | Lifevest |
| Inari Medical, INC. | $81.67 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Shockwave Medical, INC | $75.29 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $64.01 | 2021-2025 | |
| W. L. Gore & Associates, INC. | $49.53 | 2022 | |
| Amgen INC. | $22.86 | 2024 | Repatha |
| Cardiovascular Systems INC. | $20.98 | 2022-2023 | Diamondback Coronary |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vigyan Bang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.